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Abstract
Adenoviral vectors (AdV) activate multiple signaling pathways associated with innate immune responses, including
mitogen-activated protein kinases (MAPKs). In this study, we investigated how systemically-injected AdVs activate two
MAPK pathways (p38 and ERK) and the contribution of these kinases to AdV-induced cytokine and chemokine responses in
mice. Mice were injected intravenously either with a helper-dependent Ad2 vector that does not express viral genes or
transgenes, or with the Ad2 mutant ts1, which is defective in endosomal escape. We found that AdV induced rapid
phosphorylation of p38 and ERK as well as a significant cytokine response, but ts1 failed to activate p38 or ERK and induced
only a limited cytokine response. These results demonstrate that endosomal escape of virions is a critical step in the
induction of these innate pathways and responses. We then examined the roles of p38 and ERK pathways in the innate
cytokine response by administering specific kinase inhibitors to mice prior to AdV. The cytokine and chemokine response to
AdV was only modestly suppressed by a p38 inhibitor, while an ERK inhibitor has mixed effects, lowering some cytokines
and elevating others. Thus, even though p38 and ERK are rapidly activated after i.v. injection of AdV, cytokine and
chemokine responses are mostly independent of these kinases.
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Introduction
Intravenous administration of high doses of non-replicating
AdV causes a rapid innate immune response characterized by
elevated cytokines and chemokines [1–4]. Inhibiting these innate
immune responses could substantially improve the safety of AdV,
and therefore it is important to identify drugs that block AdV-
induced signaling pathways. However, not enough is known about
the signal transduction cascades that are induced by AdV in vivo,
nor whether targeting these individual signaling pathways might
broadly suppress the innate immune response to AdV.
Importantly, it is known that blocking endosomal escape of
virions prevents much of the innate response to AdV [5–7]. This
implies that the sensors and signaling pathways of the innate
immune system are triggered during or after endosomal escape of
virions, and that these pathways may primarily be located
intracellularly. MAPKs are intracellular signaling proteins that
use phosphorylation cascades to generate cellular responses to
environmental stimuli [8]. There are several classes of mammalian
MAPKs, including extracellular signal-regulated kinase 1 and 2
(ERK), c-jun N-terminal kinase (JNK) and p38 MAPK, all of
which are activated following phosphorylation by MAPK kinases
(MAPKK). The MAPKK are in turn phosphorylated by MAPKK
kinases. The ERK signaling cascade consists of Raf:MEK:ERK
and can be activated by many stimuli, including viral infection and
cytokines [8]. The p38 pathway can be activated by a variety of
receptors, including cytokine receptors and toll-like receptors
(TLRs), a family of well-studied pathogen recognition receptors
[9,10]. One important consequence of MAPK pathway activation
is the stimulation of transcription factors involved in cytokine
synthesis [11,12], and the p38 pathway in particular is being
targeted in clinical trials to treat inflammatory diseases [8,12–14].
A number of studies have shown that AdVs activate p38 and
ERK in vitro, and that these kinases are important for the induction
of certain cytokines and chemokines by cultured cells [5,15–17]. In
vivo, intravenous administration of AdV activates ERK within 15
minutes in the mouse liver, in part by signaling through Toll-like
receptor 2 via the downstream adapter molecules MyD88 and
TRIF [18,19]. However, it remains unclear whether p38 or ERK
play any essential role in mediating the innate cytokine response in
vivo, nor whether specific kinase inhibitors could be useful for
broadly suppressing innate immune responses to AdV.
In this study, we evaluated activation of MAPK pathways and
cytokine/chemokine responses after injecting mice i.v. with a
replication-deficient helper-dependent Ad2 virus (HDAd2), and
compared the response to a mutant Ad2 virus, ts1. When ts1i s
grown at the non-permissive temperature of 39uC, the resulting
virions are unable to escape from endosomes during entry [20,21].
Thus, we were able to examine whether innate responses were
triggered before or after endosomal escape of virions. We
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26755subsequently investigated how in vivo inhibition of p38 and ERK
pathways with kinase inhibitors affected the innate inflammatory
response to AdV.
Results
The ts1 mutant virus induces an attenuated cytokine/
chemokine response
To determine if endosomal escape is required for Ad to trigger
the innate inflammatory response, we injected mice i.v. with buffer
or 5610
12 viral particles (vp) per kg of either HDAd2 or ts1 grown
at the non-permissive temperature. The HDAd2 vector that we
used expresses no viral gene or transgenes, which allowed us to
examine innate immune responses triggered by the virion
components alone. Because neither HDAd2 nor ts1 expresses
genes, we were able to avoid any possible pro-inflammatory effects
that might be caused by expression of transgenes or viral genes.
Administration of HDAd2 induced a significant elevation of 11
cytokines and chemokines in the serum at 6 h, when compared to
mice receiving buffer only (Figure 1). In contrast, we found that ts1
induced a significantly attenuated innate cytokine response, failing
to induce significant levels of IL-6, IL-12 p70, KC or TNFa.
When compared to HDAd2, ts1 induced partial elevation of MCP-
1, RANTES, IFNc, IP-10, IL-1b and G-CSF, and fully induced
IL-10. The serum level of GM-CSF was not detectably altered by
HDAd2 or ts1 (not shown).
ERK and p38 MAPKs are activated in vivo by HDAd2 but
not ts1
We performed a series of experiments to examine the activation
of ERK and p38 in the liver and spleen after administration of
AdV. Appledorn et al. [18] have previously demonstrated a rapid
phosphorylation of ERK in murine liver following i.v. adminis-
tration of replication defective Ad5 vectors. We confirmed that i.v.
injection of the Ad5 vector Av1nBg induces phosphorylation of
ERK in the liver and we determined the kinetics of this response.
Mice were injected with buffer or Av1nBg at 5610
12 vp/kg and
liver lysates were evaluated by Western blot for phosphorylation of
ERK. We observed a significant elevation in ERK phosphoryla-
tion at 30 min after Av1nBg (Figure 2A). ERK phosphorylation
declined with time and was not significantly different than buffer
control mice at times 3 hours or more after vector administration.
Therefore, we chose a 30 minute time point for further
experiments.
We found that HDAd2 elevated phosphorylation of both ERK
and p38 in the liver and spleen (Figure 2B), although
phosphorylation of p38 in the spleen did not reach significance
in all experiments. In contrast, ts1 did not cause any elevation of
ERK or p38 phosphorylation. The negative results with ts1
indicate that ERK and p38 pathways are triggered during or after
endosomal escape of AdV.
Inhibition of ERK or p38 pathways with kinase inhibitors
Because of the correlation that we observed between MAPK
activation and cytokine/chemokine responses in the previous
experiments, we used kinase inhibitors to test whether activation of
the p38 or ERK pathways played any essential causal role in the
cytokine and chemokine response to HDAd2. We selected two
kinase inhibitors, PD0325901 and SB239063, based upon their
demonstrated ability to selectively inhibit ERK and p38 pathways,
respectively [22,23]. Functionally, PD0325901 inhibits the enzy-
matic activity of MEK, which is the MAPKK responsible for
phosphorylation of ERK. In contrast, SB239063 directly inhibits
p38 kinase activity. The doses we selected for oral administration
were based on the previously demonstrated pharmacological
activity of these inhibitors in rodents [22,23].
We first evaluated the ability of PD0325901 to block the in vivo
phosphorylation of ERK induced by AdV. Mice were dosed orally
with either buffer (0.5% methylcellulose) or PD0325901 one hour
before administering HDAd2. Livers and spleens were collected 30
minutes after AdV and lysates evaluated for ERK phosphoryla-
tion. When mice received PD0325901 prior to HDAd2, relative
phosphorylation of ERK in the liver and spleen was significantly
reduced (Figure 3), demonstrating the effectiveness of PD0325901
in vivo. We did not examine the in vivo inhibitory activity of
SB239063 in a similar manner because this compound inhibits
p38 activity, not p38 phosphorylation. However, we were able to
demonstrate a significant in vivo inhibitory effect of SB239063 on
LPS-induced cytokine responses (below).
To determine if these two kinase inhibitors could affect the
serum cytokine response induced by AdV, mice were orally
administered buffer, PD0325901 or SB239062, followed by
HDAd2 or LPS. A 500 mg/kg dose of LPS was used as a positive
control because this is known to activate the ERK and p38
pathways and elevate cytokines in rodents [22,24]. The MEK
inhibitor PD0325901 did not significantly inhibit the cytokine/
chemokine response to LPS (Figure 4A). In contrast, the p38
inhibitor SB239063 markedly suppressed the response to LPS
(Figure 4A). Thus, the LPS-induced cytokine/chemokine response
is considerably more dependent on the p38 pathway than on the
ERK pathway.
When mice were pre-treated with the MEK inhibitor
PD0325901 prior to HDAd2, the levels of KC and TNFa were
significantly reduced (Figure 4B). Interestingly, HDAd2 induction
of IL-6, IL-12p70, IP-10 and IFNc was significantly increased by
PD0325901, suggesting that the ERK pathway negatively
regulates production of these cytokines. Pre-treatment with the
p38 inhibitor SB239063 modestly suppressed the cytokine
response to HDAd2, significantly decreasing levels of IL-10,
IFNc, IP-10 and IL-1b (Figure 4B). Other cytokines and
chemokine responses were not significantly affected, however,
including TNFa, IL-6, IL12p70 and KC (Figure 4B). Thus,
targeting p38 had only modest and selective effects on the cytokine
and chemokine response to HDAd2, and targeting ERK actually
made some responses worse.
Discussion
The innate immune response to AdV involves the activation of
multiple sensing and signaling pathways, culminating in the
expression of inflammatory cytokines and chemokines. Depending
on the cell type, AdV can be sensed by as many as three different
classes of pathogen recognition receptors: TLRs, NOD-like
receptors and RIG-I-like receptors [3,4,18,25,26]. These receptors
activate signal transduction pathways that ultimately induce
cytokines and chemokines, but these signaling pathways have
not been extensively studied in vivo after systemic injection of AdV.
In this study we have shown that i.v. injection of a helper-
dependent AdV, devoid of any viral genes or transgenes, activates
the p38 and ERK pathways in mice. Using the mutant virus ts1w e
also found that that endosomal escape is required for activation of
these MAPK pathways and full expression of inflammatory
cytokines and chemokines. In spite of this correlation, when we
blocked activation of MAPKs we found that p38 and ERK were
not essential for most of the innate cytokine and chemokine
response to AdV.
In vitro studies have demonstrated that endosomal escape of
virions is a critical trigger for cytokine and chemokine upregula-
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detect both lysis of vesicles by AdV as well as subsequently-exposed
viral material such as AdV DNA. For example, the NLRP3
inflammasome is a key sensor of vesicle lysis, and AdV is able to
disrupt lysosomes and activate NLRP3, but ts1 is not [27]. In vivo,D i
Paolo et al. [7] found that while ts1 was taken up normally by
marginal zone macrophages in the mouse spleen, it was attenuated
in inducing certain early cytokine and chemokine responses. Fejer
et al. [6] also found that ts1 fails to induce type I interferon in mice.
In addition to ts1’s poor ability to induce cytokines and chemokines,
our in vivo studies have shown that ts1 does not trigger a variety of
other inflammatory and pathologic responses such as complement
activation and Kupffer cell killing [28,29].
In the current study, we screened a wide panel of cytokines and
chemokines and demonstrated that, compared to HDAd2, ts1i s
significantly attenuated in stimulating the secretion of many innate
inflammatory cytokines and chemokines into the blood stream
6 hours post i.v. injection. However, we found that a subset of
cytokines were partially elevated by ts1, indicating activation of
some innate immune responses even without viral penetration. A
previous study showed that ts1 can promote mRNA expression of
IL-1a in the mouse spleen at 30 minutes and small elevations of
some cytokines at 60 minutes [7]. Interestingly, the IL-1a response
in the spleen was found to be dependent on interactions between
AdV and integrins [7], and integrins have also been reported to be
involved in AdV-induced keratitis [30]. These results suggest the
possibility that activation of integrins might contribute to the
ability of ts1 to induce cytokine and chemokine responses.
MAPK pathways activate transcription factors that control
cytokine production [8]. Both ERK and JNK pathways are
Figure 1. The ts1 virus induces an attenuated cytokine/chemokine response. Mice were injected i.v. with buffer, ts1 or HDAd2 at
5610
12 vp/kg, and serum was collected six hours after injection. Compared to buffer control animals, HDAd2 induced a significant increase in the
levels of 11 cytokines and chemokines. In contrast, ts1 had a significantly attenuated response with all chemokines/cytokines except IL-10, which was
not detectably different from the IL-10 response induced by HDAd2. 5 mice/group. *=p,0.05 vs. buffer control mice; #=p,0.05 vs. mice that
received ts1 (ANOVA, Holm-Sidak).
doi:10.1371/journal.pone.0026755.g001
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AP-1, which regulates many cytokine genes, and the p38 pathway
is involved in the induction of multiple pro-inflammatory cytokines
[12]. Although we were unable to detect induction of JNK by AdV
in the liver or spleen (data not shown), JNK has been shown to
play a critical role in the type I interferon response to AdV both in
vitro and in vivo [6]. Regarding the role of ERK, this MAPK is
activated by AdV both in vitro and in vivo [5,15,17,18]. Regarding
p38, AdV activates p38 in cultured cells [5,16], but whether p38 is
activated by AdV has not previously been measured in vivo.
In vitro studies have indicated a correlation between endosomal
escape of AdV and MAPK activation. Tibbles et al. [5]
demonstrated that blocking endosomal acidification inhibited
p38 and ERK phosphorylation in epithelial cells, and Suomalai-
nen et al. [16] found that ts1 was deficient in stimulating p38 in
HeLa cells. Because the kinase response to ts1 had not previously
been examined in vivo, we quantitated ERK and p38 phosphor-
ylation in mouse liver and spleen. AdV induced phosphorylation
of both ERK and p38 within 30 min in vivo. In contrast, we found
that ts1 failed to elevate the phosphorylation of either of these two
MAPKs, indicating a correlation among endosomal escape,
activation of MAPK pathways and the cytokine and chemokine
response to AdV.
To determine whether p38 or ERK plays any critical role in the
AdV-induced cytokine response, we administered two specific
MAPK inhibitors to mice. The ERK pathway inhibitor,
PD0325901, is a specific non-ATP competitive inhibitor of
MEK, with well described pharmacokinetics, that blocks the
Figure 3. The MEK inhibitor PD0325901 significantly blocks
AdV-induced phosphorylation of ERK in the liver and spleen.
Mice were orally administered 10 ml/kg of vehicle (0.5% methylcellu-
lose) or 100 mg/kg of a MEK inhibitor (PD0325901), and all mice were
injected i.v. with HDAd2 60 minutes later. Livers and spleens were
collected 30 minutes after HDAd2 for Western blot. Data are normalized
to the vehicle control group. 4 mice/group * p,0.01 for vehicle control
vs. PD0325901 (t-test).
doi:10.1371/journal.pone.0026755.g003
Figure 2. Activation of ERK and p38 by AdV in mouse liver and
spleen. Phospho-ERK (p-ERK1/2) and phospo-p38 (p-p38) were
quantitated by Western blot using phospho-specific antibodies. A.
Av1nBg, injected i.v. at 5610
12 vp/kg, induced a rapid phosphorylation
of ERK in the mouse liver, with a peak appearing at 30 min. *=p,0.05
vs. 30 min buffer control mice (ANOVA, Holm-Sidak). B. HDAd2
significantly induced phosphorylation of ERK in the liver and spleen
and p38 in the liver at 30 minutes, but ts1 did not. Data are normalized
to the buffer control group. 5 mice/group. *=p,0.05 vs. buffer control
mice (ANOVA, Holm-Sidak).
doi:10.1371/journal.pone.0026755.g002
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either 8 ml/kg buffer, 100 mg/kg of the MEK (ERK pathway) inhibitor PD0325901 or 40 mg/kg of the p38 inhibitor SB239063. Sixty minutes later mice
were injected i.v. with 5610
12 vp/kg HDAd2 or i.p. with 500 mg/kg LPS. Serum was collected at either 2 hours (LPS) or six hours (HDAd2) and
evaluated for cytokine levels. A. The cytokine response to LPS was unaltered by inhibition of the ERK pathway with the exception of IP-10, which was
signficantly elevated (left panel). In contrast, inhibition of the p38 pathway significantly reduced the response to LPS for all the tested chemokines/
cytokines except KC (right panel). B. Inhibition of the ERK pathway altered the cytokine/chemokine response to HDAd2 (left panel), significantly
inhibiting the serum levels of TNFa and KC and significantly elevating the expression of IL-12p70, IFNc, IP-10 and IL-6. Pretreatment with the p38
MAPKs and the Innate Response to Ad Vectors
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PD0325901 was effective in blocking HDAd2-induced ERK
phosphorylation. The p38 inhibitor SB239063 blocks the kinase
activity of p38 and has been shown to inhibit the production of
LPS-induced cytokines [22]. We confirmed the in vivo activity of
SB239063 in our experiments by showing that it markedly
suppressed the cytokine and chemokine response to LPS.
We found that inhibition of MEK did not suppress the cytokine
response to LPS and only inhibited the induction of one AdV-
induced cytokine (TNF-a) and one AdV-induced chemokine
(KC). Interestingly, blocking ERK phosphorylation actually
enhanced AdV induction of IL-6, IL-12p70, IP-10 and IFNc.
This finding suggests that the ERK pathway may contribute to
feedback inhibition of these cytokines. Our results on serum IP-10
at 6 h after AdV contrast with those of Tibbles et al. [5], who
reported that a different MEK inhibitor partially suppressed IP-
10 mRNA levels in liver at an early timepoint after AdV (1 h).
These authors also found that a p38 inhibitor was partially
suppressive for IP-10 mRNA. However, they reported that the
effect of the p38 inhibitor did not persist beyond 1 h, and by 6 h
the IP-10 mRNA response to AdV was similar regardless of
whether a p38 inhibitor was used [5]. It is possible that the
earliest steps of AdV-induced innate immune responses in certain
organs are partially dependent on p38 or ERK, but redundant
pathways eventually allow full peak serum levels of cytokine and
chemokine.
When we examined the effect of a p38 inhibitor on the AdV-
induced response, we found a partial but statistically-significant
reduction in 4 of the 8 tested cytokines and chemokines. Clearly,
the majority of the AdV-induced response did not require p38
activity. In contrast, the response to LPS was nearly eliminated by
the p38 inhibitor, with a significant reduction in 7 of the 8 tested
cytokines and chemokines and a non-significant reduction in the
serum level of KC.
The discordance between the effectiveness of the p38 inhibitor
at inhibiting the response to LPS, but not the response to AdV,
highlights the complexity of the innate response to AdV. This
makes sense in light of the known redundancy of innate immune
sensors that can detect AdV. For example, the cytokine response
to LPS is mediated through TLR4 [31], but studies on the innate
response to AdV have demonstrated involvement of multiple
TLRs including TLR2, TLR3, TLR4 and TLR9, each of which
partially contributes to sensing AdV [18,19,32,33]. In addition, a
number of other innate sensors also detect AdVs, including
NOD-like receptors and RIG-I-like receptors [4]. Thus, AdV
activates a wider variety of sensors than LPS and the resulting
network of responses is far more complex, with the implication
that using drugs to target single pathways may only show limited
effectiveness in decreasing the broad innate immune response to
AdV.
In conclusion, although small-molecule drugs that interfere with
MAPK pathways are thought to have promise as anti-inflamma-
tory drugs, we found that neither the ERK nor p38 pathways
played an essential role in the broad cytokine and chemokine
response to AdV. Nevertheless, these results add important
knowledge to our understanding of the roles of MAPKs in vivo.
Given the complexity of the innate immune reaction to
systemically injected AdV, it seems likely that one will need to
target multiple pathways simultaneously to achieve meaningful
suppression of the innate response to AdV.
Materials and Methods
Ethics Statement
All animal protocols and procedures were approved by the FDA
CBER Animal Care and Use Committee (protocol #2003-11) in
animal facilities accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care International. All
experiments were performed according to institutional guidelines.
Viruses
The helper-dependent Ad2 virus HDAd2D28E4 (HDAd2) was
generated by rescuing the HDAd plasmid pD28E4 (Toietta et al.,
2002) with the Ad serotype 2 helper virus Ad2LC8cCARP (Parks
et al., 1999) in 116 cells as described elsewhere (Palmer and Ng,
2003). pD28E4 has a 28 kb genome that is composed of Ad5
derived inverted terminal repeats and a packaging signal, followed
by two non-coding mammalian stuffer sequences and has no
transgene [34]. The Ad2 mutant ts1 was grown at 39uC and
characterized as previously described [28]. The particle:pfu ratio
of ts1 was greatly elevated (1610
5), as expected. A replication-
defective E1/E3-deleted Ad5 vector expressing nuclear-localized
b-galactosidase (Av1nBg) was used for certain experiments [35].
Viruses were purified by double (for ts1 and Av1nBg) or triple
(for HDAd2) CsCl ultracentrifugation as described previously
[36,37]. Ad concentration was measured spectrophotometrically
by the OD260 method, with no detectable aggregation, as
previously described [36,38]. Endotoxin levels in all substances
injected into mice were ,0.15 EU/ml by the LAL method
(Charles River Endosafe, Charleston SC).
Animals
Male C57BL/6NCr or C57BL/6J mice were obtained from the
National Cancer Institute (Frederick, MD, USA) or Jackson Labs
(Bar Harbor, ME) respectively. The mice were maintained in our
specific pathogen-free facilities, and used at 8–10 weeks of age. For
some experiments the ERK inhibitor PD0325901 (100 mg/kg,
Selleck Chemicals, Houston, TX), suspended in 0.5% aqueous
methylcellulose (Sigma), or the p38 inhibitor SB239063 (40 mg/
kg, Tocris Biosciences, Ellisville, MO), suspended in an aqueous
solution of 0.5% tragacanth (Sigma) containing 0.05N HCl
(acidified tragacanth), were administered per os. For per os
administrations, awake mice were restrained by hand and buffer
or inhibitors administered directly into the stomach at 10 ml/kg
through a 20G, 1.50, curved feeding needle with a 2.25 mm ball
tip. LPS from E. coli 026:B6 (Sigma, St. Louis, MO) was prepared
in phosphate buffered saline and administered i.p. at 0.5 mg/kg.
For tail vein injections of AdV, awake mice were restrained in a
cylindrical device and a dose of 5610
12 vp/kg was administered at
8.0 ml/kg over approximately 5 s. Five to 10 min prior to
sacrifice, animals were anesthetized by intraperitoneal injection
with 150 mg/kg ketamine and 30 mg/kg xylazine. For serum
collections, blood was obtained by cardiac puncture. For Western
blots, livers and spleens were removed, placed in microfuge tubes,
immediately frozen on dry ice and transferred to 280uC freezer
until lysed for Western blots as described below.
Western Blots
Frozen liver and spleen fragments, weighing between 150–
250 mg and 50–120 mg respectively, were homogenized on a
Bullet Blender (Next Advance) in 400–500 ml chilled lysis buffer
inhibitor (right panel) significantly decreased the serum levels of IFNc, IL-10 and IL-1b. The buffer controls were 0.5% methylcellulose and 0.5%
acidified tragacanth for the ERK and p38 inhibitors, respectively. 3–5 mice/group, *=p,0.05 vs. corresponding buffer control (t-test).
doi:10.1371/journal.pone.0026755.g004
MAPKs and the Innate Response to Ad Vectors
PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e26755(20 mM Tris-HCL, pH 7.4, 1 mM EDTA and 150 mM NaCl)
containing 1% Triton X-100. A protease inhibitor cocktail (Sigma
#P8340) and phosphatase inhibitor cocktail 1 (Sigma #P0044)
were added to the lysis buffer at 1% just prior to use. Lysates were
cleared at 12,000 g, 4uC, for 10 minutes, and protein concentra-
tions determined (DC protein assay, Bio-Rad, Hercules CA) prior
to storage at 280uC. For Western blotting, equal amounts of
protein samples were run on polyacrylamide gels and transferred
to nitrocellulose membranes. Membranes were probed with
primary antibodies to ERK2 (Santa-Cruz sc-81458), p38 (Santa
Cruz sc-7972), phosphorylated-ERK1/2 (Cell Signaling-Danvers,
MA) #4370S or phosphorylated p38 (Cell Signaling) #4511 and
detection performed using fluorescent secondary antibodies from
Odyssey/LI-COR (Lincoln, Nebraska). Blots were scanned and
bands quantified by fluorescent intensity using a LI-COR scanner.
For data analysis, the amount of phosphorylated ERK1/2 was
normalized to total ERK2 protein as described by Appledorn et al.
[18]. Similarly, phosphorylated p38 was normalized to total p38.
Cytokines and chemokines
Serum chemokine/cytokine concentrations were evaluated
using singleplex and multiplexed assay kits from Meso Scale
Discovery (MSD, Gaithersburg, MD) or ELISA kits from R&D
systems (Minneapolis, MN). Specifically, serum was used in
multiplex (7-plex mouse pro-inflammatory) kits from MSD to
evaluate IFN-c, IL-10, IL-12p70, IL-1b, IL-6, KC and TNF-a.
Singleplex assays from MSD were used for MCP-1, GM-CSF and
RANTES. When required due to exceeding upper limit of
detection, an MSD singleplex was used for IL-6. MSD plates were
evaluated on an MSD Sector Imager 2400, model 1250. Mouse
Quantikine kits from R&D systems were used for detection of G-
CSF and IP-10. In all cases samples were assayed in duplicate.
Statistical analysis
In all figures, mean 6 SD is shown. Data were log-transformed
to equalize variances among groups, and then analyzed by either t-
test or ANOVA, depending on the number of groups in the
experiment. For ANOVA, post-hoc comparisons between control
and test groups were made using the Holm-Sidak test (SigmaPlot
11.0, Systat Software, San Jose CA). Significance was defined as
p#0.05.
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